The rise of China's in vitro diagnostics industry: Evolution from local innovation to global leadership

In the early 1990s, China's in vitro diagnostics (IVD) industry began to develop, propelled by rising demand for diagnostic tools and expanding healthcare infrastructure. This period saw a mix of domestic manufacturers and import agencies providing foreign diagnostic products. The industry began aligning with national standards and quality control systems, while also establishing the foundational stages of a local supply chain. In this context, the China International In Vitro Diagnostic Expo by CACLP, launched in 1991 as one of the first industry communication platforms, facilitated the initial aggregation of the IVD supply chain. At the start of the 21st century, the global IVD industry grew rapidly, with China emerging as one of the fastest-growing markets due to its large population and healthcare needs. China's accession to the World Trade Organization in 2001 marked a key milestone, allowing it to compete globally. Recognizing the potential of China's market, foreign enterprises aggressively entered to introduce integrated offerings of reagents and instruments with advanced, domestically unavailable technologies, thereby capturing significant market share. In response to foreign competition, domestic IVD companies strengthened their technological capabilities and expanded their product offerings. Backed by government initiatives and growing healthcare investments, the domestic IVD industry entered a period of rapid growth, drawing significant capital market interest. In the 2010s, China's IVD industry underwent significant structural optimization, evolving from standalone production to a fully integrated supply chain encompassing raw materials through to complete diagnostic systems. This integration boosted China's global competitiveness in diagnostics, enabling local companies to export their products internationally. A consensus emerged during this transformative period about the promising prospects for IVD industry development. Academic exchanges and industry fairs thrived, promoting collaboration and knowledge-sharing. In 2004, CACLP rebranded, and subsequent academic conferences such as the China IVD Industry Development Conference and the China Experimental Medicine Conference were introduced, highlighting the significance of research and development. The coronavirus disease 2019 pandemic represented a critical turning point for China's IVD industry. As global demand for diagnostics surged, Chinese companies rapidly produced and distributed test kits and diagnostic tools, positioning China as a major supplier to domestic and international markets. The pandemic further accelerated technological innovations within the industry, particularly in molecular diagnostics, rapid point-of-care testing, and digital health solutions. By 2023, with China reopening its borders and resuming international trade, the IVD industry witnessed a new wave of internationalization. Chinese companies expanded their global presence through technical partnerships, joint ventures, and broadened distribution networks. This globalization trend is evident in CACLP's strategic international partnerships with organizations such as the International Federation of Clinical Chemistry and Laboratory Medicine, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and the Association for Diagnostics & Laboratory Medicine, as well as IVD associations and national consulates in the UK, Germany, Japan, Korea, and India. By 2024, the number of international exhibitors, visitors, and participating countries is expected to reach record levels, further positioning CACLP as a prominent player in the global IVD sector. Looking forward, several key trends are anticipated to shape the future of the IVD industry. Emerging technologies such as precision medicine, next-generation sequencing, microfluidics, and digital diagnostics are set to drive innovation in domestic and global markets. Chinese companies are expected to continue investing in R&D and forming new partnerships to remain competitive in this rapidly evolving industry. Growing demand for personalized medicine and point-of-care testing presents new opportunities for both local and international players. With demonstrated resilience and adaptability, China's IVD sector is well-positioned to capitalize on these trends and expand its global influence. CACLP, now one of the world's largest IVD exhibitions, is committed to “Bringing IVD People Together” to showcase the latest innovations and promote global collaboration at its upcoming event from March 22–24, 2025, in Hangzhou, China. The development of China's IVD industry mirrors the broader narrative of China's globalization. From its beginnings in the 1990s to its role today as a global diagnostics leader, China's IVD industry has played a critical role in shaping healthcare domestically and globally. Looking forward, China's IVD sector is poised to lead diagnostic innovation, fostering collaborations that will advance global healthcare in the years to come.